Navigation Links
GSK Receives FDA Approval for MenHibrix®
Date:6/14/2012

PHILADELPHIA, June 14, 2012 /PRNewswire/ -- GlaxoSmithKline plc (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix® [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine]. MenHibrix is a vaccine indicated to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MenHibrix is approved for use in children aged six weeks through 18 months.

The vaccination schedule for MenHibrix is a four-dose series given at two, four, six, and 12 through 15 months of age. The first dose can be given as early as six weeks of age and the last as late as 18 months of age. MenHibrix was developed to align with the Centers for Disease Control and Prevention's recommended infant immunization schedule for Hib vaccination and to allow for vaccination against meningococcal groups C & Y without adding additional shots. GSK will provide additional details on when MenHibrix will be available in the near future.

"All of us at GSK Vaccines look at today's approval as a good day for infants, toddlers and healthcare providers," said Leonard Friedland, M.D., Vice President, Head, Clinical and Medical Affairs, North America Vaccine Development, GSK Vaccines. "MenHibrix gives healthcare providers the option of combining Hib immunization with meningococcal C and Y immunization without increasing the number of shots for infants and toddlers."

The basis for FDA approval of MenHibrix included data GSK submitted from clinical trials conducted in the United States, Mexico, Australia, Belgium and Germany over seven years in which 7,521 infants and toddlers received at least one dose of MenHibrix. Of these participants, 3,349 were located in the United States.  Adverse events in clinical trials included pain and redness at t
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
3. Nephros Receives 510(k) Clearance for Hemodiafiltration System
4. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
5. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
6. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
7. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
8. Alexza Receives Complete Response Letter for Adasuve™ NDA
9. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
10. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
11. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 InVivo Therapeutics Holdings Corp. ... is revolutionizing spinal cord injury (SCI) treatment with ... to outperform in tissue regrowth in the spinal cord ... from an FDA approved polymer, the scaffold ultimately breaks ... to the human body. NVIV has recently attracted significant ...
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... Two new analyses of observational,data presented at today,s ... patients receiving transfusions when,erythropoiesis- stimulating agents (ESAs) treatment ... 11 grams per deciliter (g/dL) of blood,compared with ... prior to ESA,treatment. In addition, wide variability in ...
... of innovative,Therapeutics Development Initiative, NEW YORK, Jan. 31 ... it takes to speed delivery of transformative,treatments and a ... Parkinson,s Research has awarded up to $3 million in ... new PD treatments,closer to the clinic. The awards were ...
Cached Medicine Technology:Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 2Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 3Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 4Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents 5Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... Black women undergoing in vitro fertilization (IVF) are only about ... the popular assisted reproduction technique, new research indicates, and the ... In the study, about 31 percent of white patients became ... patients. Analyzing more than 4,000 IVF cycles over two ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
(Date:10/22/2014)... taken by Firestone officials at the company,s rubber ... spread of the disease there and could prove effective ... provides health services to about 80,000 employees, retirees, their ... Between Aug. 1 and Sept. 23, there were 71 ... That incidence rate of 0.09 percent was much lower ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... ... Berkeley Heights campus. , ... January 15, 2010 -- Kanan Shridharani, MD, has recently joined Summit Medical Group’s Internal Medicine ... University , New York, NY in 1986. She went on to earn her MD in ...
... may stave off eye disease, research suggests, , FRIDAY, Jan. ... many calories and too much sodium increase their risk for ... 469 black participants who had type 1 diabetes. Six years ... and had photos taken of their eyes to determine the ...
... , PALM DESERT, Calif. , ... superstar Katy Perry has signed on to appear ... experience fighting acne and finding Proactiv® Solution .  Katy ... exciting new 2010 campaign which will introduce new technology and ...
... a common gastrointestinal functional disorder that can greatly ... including alterations in the intestinal microbiota, are suspected ... article to be published on December 21, 2009 ... addresses this question. The research team from Finland ...
... It is reasonable to obtain a histological diagnosis before ... or unwilling to undergo surgery. As the pancreas is ... it is a challenge for the physician to obtain ... of pancreatic masses has been proved to be a ...
... the most common chronic disease of the world and ... Taiwan. Gastroparesis is reported in 5% to 12% of ... uncommon disease resulting compression of the third portion of ... syndrome can cause the same symptoms as diabetic gastroparesis. ...
Cached Medicine News:Health News:Summit Medical Group Welcomes Kanan Shridharani, M.D. 2Health News:Blacks With Diabetes Urged to Cut Calories, Salt 2Health News:Singer-Songwriter Katy Perry Signs On to Tell Proactiv(R) Story 2Health News:Singer-Songwriter Katy Perry Signs On to Tell Proactiv(R) Story 3Health News:Singer-Songwriter Katy Perry Signs On to Tell Proactiv(R) Story 4
... purified non-ionic fraction of agar. Forms gel ... concentrations. Can be mounted on microscope slides ... elastic and durable and show little or ... or lipoprotein dyes. Contaminants: ash: ...
... Certified PCR agarose is recommended for separations ... agarose forms gels that are easy to ... gel percentages, which minimizes the risk of ... genetic quality tested (GQT) products with similar ...
... Agarose-HR™ High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
The reading of agglutinations process in Diana Reader is by image treatment which allows great sensitivity....
Medicine Products: